Lilly's Alzheimer's drug gets UK nod but won't be NHS-funded
The UK medicines regulator approved Eli Lilly's Alzheimer's disease therapy Kisunla today, but the drug is too expensive to be funded by the NHS, according to cost-effectiveness watchdog NICE. GB is the first country in Europe to approve amyloid inhibitor Kisunla (donanemab) and only the third to do so worldwide after the US and Japan.
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and ...
Discussing Pfizer's platform, the lawmakers write that it "creates the impression that any patient interested in a particular ...
A group of U.S. senators are digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this ...
Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers ...
Maggie Lilly is creating a buzz with her Party of Hive granola.
"Slim Aarons: Gold Coast" is organized by Shawn Waldron, the curator for Getty Images and manager of the Slim Aarons Archive ...
The News Leader (Staunton) on MSN15h
Five Waynesboro residents ask judge to force Lilly and Mares to certify upcoming electionA counter lawsuit asking a judge to force two Waynesboro Board of Election members to certify the Nov. 5 election was filed ...
Eli Lilly & Co. closed $63.38 below its 52-week high ($972.53), which the company reached on August 22nd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback